Pei Ho


pei.ho.wg11@wharton.upenn.edu Harvard University, Cambridge, MA A.B., Biology, 2002


Todd M. Holmes todd.holmes.wg11@wharton.upenn.edu


Colgate University, Hamilton, NY B.A., Economics and Latin American Studies, 2003


Uttam Jain


uttam.jain.wg11@wharton.upenn.edu Indian Institute of Technology, Bombay, India B.Tech., Institute Medal, Chemical Engineering, 2001 Massachusetts Institute of Technology, Cambridge, MA


MS, Frederic A.L. Hollaway Fellowship, Chemical Engineering Practice, 2003


An opportunity within an entrepreneur- ial team in the medical device industry.


Amgen Inc., Thousand Oaks, CA Commercial Leadership Program Intern, EPOGEN Brand Team, Summer 2010 Led cross-functional team to design marketing strategy for peritoneal dialysis segment of erythropoiesis- stimulating agent market in response to new entrants and changes to Medicare’s end-stage renal disease prospective payment system.


Extera Partners, Cambridge, MA Senior Associate, 2008-2009


Led 1-2-person case teams to develop and execute strategy and business development recommendations to early-stage life science companies. Casework included directing regulatory and commercial strategy for venture-backed medical device company developing novel technology for $200M segment of interventional cardiology market.


Oxford Bioscience Partners, Boston, MA Analyst, 2006-2008


Participated in all aspects of closing 6 new $5-7M life science-focused venture capital investments, including deal sourcing, market research, finan- cial analysis/modeling, intellectual property review, and term sheet negotiation.


Fletcher Spaght & Fletcher Spaght Ventures, Cambridge, MA Analyst, 2004-2006


Provided strategic guidance to primarily venture-backed companies in life science industry. Conducted due diligence on potential Fletcher Spaght Ventures investments.


An opportunity at a health care-focused investment fund or in an operations role at a start-up.


SR One, Conshohocken, PA Summer Associate, Summer 2010 For SR One–led Series B financing, completed scientific diligence and market analysis; authored investment memorandum approved by GSK’s CEO and Chairman R&D; and led term sheet negotiations, deal syndication and IP diligence. Performed exit scenario modeling for completed bridge financing, profiled emerging therapeutic landscapes, conducted sector investment overviews, and evaluated drug discovery and development companies.


BVF Partners, San Francisco, CA Associate, 2005-2009


Managed all-encompassing investment processes including market screens, stock analysis, financial modeling, scientific diligence, and term sheet negotiations. Drove majority of fund’s sourcing and fundamental due diligence efforts, resulting in tens of long-term investment positions. Actively managed portfolio companies and expanded operations involvement by engaging management on business development efforts and creative financing and strategic alternatives.


SVB Financial Group, Palo Alto, CA Associate, 2004-2005 Credit Analyst, 2004


Underwrote high-risk debt facilities to VC-backed life sciences and technolo- gy start-ups. Performed financial modeling, qualitative analysis, and evaluation of asset strength and receivable reliability. Oversaw analyst team that supported region’s technology practices.


An opportunity to work with a promis- ing team of private equity investors with interest in health care services and medical device sectors.


Apax Partners, London, UK Summer Associate, Summer 2010 Evaluated $1B+ public-to-private investment opportunities for a Singapore-listed medical device company, a London-listed health care services company and a NYSE-listed medical device company. Performed and led commercial diligence, created operating models and developed investment thesis for investment committees.


Riverside Partners, Boston, MA Associate, 2007-2009


Performed rigorous business due- diligence for prospective investments, built valuation models, supported deal structuring, and assisted Board of Directors in portfolio management activities. Conducted diligence for 14 potential and 4 completed invest- ments. Selected transactions include: Tegra Medical, leading outsourced medical-device manufacturer for orthopedic and cardiovascular OEMs; and Alteris Renewables, largest solar integrator in New England.


The Boston Consulting Group, Boston, MA


Consultant, 2004-2007 Top-tier Consultant with strong skills in strategic thinking and hypotheses structuring. Selected projects include: Generic drugs supply chain strategy for a leading pharmaceutical company; Technology assessment and growth strategy for a major medical devices company.


16


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40